fda
Non-nutritive Sweeteners Affect Human Microbiomes and Can Alter Glycemic Responses
Since the late 1800s non-nutritive sweeteners have promised to deliver all the sweetness of sugar with none of the calories. They have long been believed to have no effect on the human body, but researchers challenge this notion by finding that these sugar substitutes are not inert, and, in fact, some can alter human consumers’ ...
FDA’s Long-sought Guidance on NAC Follows NPA’s Lawsuit and Citizen’s Petition
Following a Citizen’s petition and lawsuit filed by the Natural Products Association (NPA) against the U.S. Food and Drug Administration (FDA) for a dietary supplement issued enforcement discretion for N-Acetyl-Cysteine (NAC) has resulted in the agency issuing final guidance. “This is a big win but it is bittersweet for sure. Although it was NPA’s leadership ...
NPA Responds to Report of Increased, Unintentional Pediatric Melatonin Ingestion
Over the past decade and particularly since the beginning of the COVID-19 pandemic, the use of melatonin supplements to address sleep issues has increased significantly by both adults and children. On Thursday, June 3, the Centers for Disease Control and Prevention (CDC) released a 10-year study that found a sharp increase in the use of ...
NSF and SCNM’s School of Nutrition Collaborate on New Master of Science Program
The Southwest College of Naturopathic Medicine & Health Sciences (SCNM, Tempe, AZ) has announced a one-of-a-kind course created by a collaboration between NSF, the global leader in health standards, and the School of Nutrition’s Executive Master of Science in Nutrition Business Leadership (MSNBL) program. The curriculum is designed exclusively for emerging and existing nutrition industry ...
FDA Announces Qualified Health Claim for Magnesium and Reduced Risk of High Blood Pressure
In a letter of enforcement discretion released on Jan 10., the U.S. Food and Drug Administration (FDA) announced that it does not intend to object to the use of certain qualified health claims regarding the consumption of magnesium and a reduced risk of high blood pressure (hypertension), provided that the claims are appropriately worded to avoid misleading ...
Associations Comment on the Nomination of Robert M. Califf For FDA Commissioner
On Nov. 12, President Biden announced that he will nominate Robert M. Califf, MD for commissioner of the U.S. Food and Drug Administration (FDA). Califf is an internationally recognized expert in clinical trial research, health disparities, health care quality and cardiovascular medicine. He has nearly four decades of experience as a doctor, researcher, leader and ...
Associations Denounce FDA Rejection of NDI Notifications for Hemp Extract Containing CBD
The Council for Responsible Nutrition (CRN) and the Natural Products Association (NPA) have denounced the U.S. Food and Drug Administration’s (FDA) rejection of two new dietary ingredient (NDI) notifications for full-spectrum hemp extract containing cannabidiol (CBD)—and urged Congress to act on pending legislative proposals that require the agency to address the lack of regulation of hemp-derived ...
Meta-Analysis Finds That Omega-3 Fatty Acids Improved Cardiovascular Outcomes
For decades, there has been great interest in whether omega-3 fatty acids can lower rates of cardiovascular events. In 2018, results from the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) were published in the New England Journal of Medicine and showed that a high dose of a purified ethyl ester of eicosapentaenoic acid (EPA) in ...
New Draft Legislation Sets Safe Level of Consumption for CBD Products
New draft legislation includes a provision directing the U.S. Food and Drug Administration (FDA) to set a safe level of consumption for CBD products. The provision is part of a broader bill introduced by Senator Chuck Schumer (D-NY) that would decriminalize cannabis at the federal level. “Setting a safe level of consumption for CBD products ...
FDA Warns Selling of Topical CBD Products Violates FD&C Act
On March 22, the U.S. Food and Drug Administration (FDA) stated that it has issued warning letters to two companies for selling topical pain relief products labeled as containing cannabidiol (CBD) in ways that violate the Federal Food, Drug and Cosmetic Act (FD&C Act). Specifically, the warning letters addressed the illegal marketing of unapproved drugs ...
Don't Miss Out!
Industry Professionals
Stay Informed!
Stay informed about the latest health, nutrition, and wellness developments by signing up for a FREE subscription to Natural Practitioner magazine and digital newsletter.
Once subscribed, you will receive industry insights, product trends, and important news directly to your doorstep and inbox.
